Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA

Sikander Ailawadhi, Sarah M. Larson, Shannon Ferrante, Nicole Rafalko, Niodita Gupta-Werner, Jennifer S. Harper, Rohan Medhekar, Marjohn Armoon, Annelore Cortoos, Shuchita Kaila, Shebli Atrash

Blood (2024) 144 (Supplement 1): 2381.

https://doi.org/10.1182/blood-2024-199085

Published: 2024

Journal Articles

Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study

Blood (2024) 144 (Supplement 1): 3760.

https://doi.org/10.1182/blood-2024-201712

Published: 2024

Journal Articles

First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Sarah M. Larson, Umar Farooq, Boyu Hu, Tahir Latif, Felix A. Mensah, Deepthi Kolli, Giulia Parisi, Greg P. Kaufman, Jonathan E. Benjamin, Akil Merchant

Blood (2024) 144 (Supplement 1): 4824.

https://doi.org/10.1182/blood-2024-200697

Published: 2024

Journal Articles

Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

Blood (2024) 144 (Supplement 1): 675.

https://doi.org/10.1182/blood-2024-201736

Published: 2024

Journal Articles

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone (DIPD) As Salvage Therapy in Early Relapsed/Refractory Multiple Myeloma

Anupama Kumar, Aaron S. Rosenberg, Edward D. Ball, Sarah M. Larson, Lindsey Sirianni, Carolyn M. Mulroney, Caitlin L. Costello

Blood (2023) 142 (Supplement 1): 4750.

https://doi.org/10.1182/blood-2023-181091

Published: 2023

Journal Articles

Updated Follow-up of a Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3490.

https://doi.org/10.1182/blood-2023-186636

Published: 2023

Journal Articles

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

Nizar J Bahlis, Suzanne Trudel, Christopher Maisel, Lisa X. Lee, Jorge Monge, Claudia Paba Prada, Sarah M. Larson, Guenther Koehne, Yogesh Jethava, Wei Dong Ma, Cristina De Nicolo, Isabel Perez-Cruz

Blood (2023) 142 (Supplement 1): 6737.

https://doi.org/10.1182/blood-2023-189700

Published: 2023

Journal Articles

A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)

Sarah M. Larson, Yvonne Y Chen, Jim Johnston, Sylvain Roy, Pinakin Patel, Jonathan E Benjamin

Blood (2023) 142 (Supplement 1): 6892.

https://doi.org/10.1182/blood-2023-187614

Published: 2023

Journal Articles

Deliriogenic Medication Use in Older Adults Receiving CAR-T Correlates with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Michael J. Maranzano, Justin Cheng, John Timmerman, Patricia A. Young, Caspian H. Oliai, Herbert A. Eradat, Sven de Vos, Sarah M. Larson, Monica Mead

Blood (2023) 142 (Supplement 1): 7358.

https://doi.org/10.1182/blood-2023-182105

Published: 2023

Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Blood (2021) 138 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2021-146783

Published: 2021

Journal Articles

Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma

Sarah M Larson, MD, Mao Yu Peng, PhD, Monica Mead, MD BS, Andrae Vandross, MD, Dylan Conklin, PhD, Erika Von Euw, PhD, Dennis J. Slamon, MD PhD

Blood (2017) 130 (Supplement 1): 3084.

https://doi.org/10.1182/blood.V130.Suppl_1.3084.3084

Published: 2017

Journal Articles

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Neil P. Shah, MD PhD, Jose Valentín García Gutiérrez, PhD, Antonio Jiménez-Velasco, MD, Sarah M Larson, MD, Susanne Saussele, MD, Delphine Rea, MD, François-Xavier Mahon, MD PhD, Moshe Levy, MD, María Teresa Gómez-Casares, MD PhD, Fabrizio Pane, MD, Franck-Emmanuel Nicolini, MD PhD, Michael J. Mauro, MD, Oumar Sy, PhD, Patricia Martin-Regueira, MD, Jeffrey H. Lipton, PhD MD FRCPC

Blood (2017) 130 (Supplement 1): 314.

https://doi.org/10.1182/blood.V130.Suppl_1.314.314

Published: 2017

Journal Articles

Outcomes of Classical Hodgkin Lymphoma in US Hematology Practices: Initial Data from a Prospective Real-World Study

Christopher A. Yasenchak, MD, Jakub Svoboda, MD, Sarah M Larson, MD, Don A Stevens, MD, Srikanth Gajavelli, MD, Trong Kim Le, Philippe Armand, MD PhD

Blood (2017) 130 (Supplement 1): 5626.

https://doi.org/10.1182/blood.V130.Suppl_1.5626.5626

Published: 2017

Journal Articles

Activity of the Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Copanlisib, As a Single Agent and in Combination with Carfilzomib in Multiple Myeloma

Sarah M Larson, MD, Mao Yu Peng, PhD, Andrae Vandross, MD, Monica Mead, MD BS, Zoe Fuchs, Dylan Conklin, PhD, Erika Von Euw, PhD BS, Dennis J. Slamon, MD PhD

Blood (2016) 128 (22): 5665.

https://doi.org/10.1182/blood.V128.22.5665.5665

Published: 2016

Journal Articles

Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications

Roy L. Kao, MD, Eric H. Gschweng, BS, Avigael Rebecca Lerman, Sarah M. Larson, MD, Andy Tu, Tulika Tyagi, MS, Shantha Senadheera, MS, Roger P. Hollis, PhD, Satiro N. De Oliveira, MD

Blood (2014) 124 (21): 3497.

https://doi.org/10.1182/blood.V124.21.3497.3497

Published: 2014

Journal Articles

Second-Generation Chimeric Antigen Receptors Successfully Modify Hematopoietic Stem Cells for Immunotherapy of B-Lineage Malignancies

Roy L. Kao, MD, Tulika Tyagi, MS, Sarah M. Larson, MD, Andy Tu, Shantha Senadheera, MS, Roger P. Hollis, PhD, Satiro N. De Oliveira, MD

Blood (2014) 124 (21): 655.

https://doi.org/10.1182/blood.V124.21.655.655

Published: 2014

Journal Articles

Anti-CD19 Chimeric Antigen Receptor Controlled By The Suicide Gene HSVsr39TK In Hematopoietic Stem Cells For Immunotherapy Of B-Lineage Malignancies

Sarah M. Larson, MD, Andy Tu, Shanta Senadheera, Michelle Ho, BS, Donald B. Kohn, MD, Satiro deOliveira, MD

Blood (2013) 122 (21): 1659.

https://doi.org/10.1182/blood.V122.21.1659.1659

Published: 2013

NARROW

Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma Retreated with Daratumumab in Real-World Clinical Practice in the USA

Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study

First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone (DIPD) As Salvage Therapy in Early Relapsed/Refractory Multiple Myeloma

Updated Follow-up of a Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol

A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)

Deliriogenic Medication Use in Older Adults Receiving CAR-T Correlates with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Inhibition of PI3K Alpha and PI3K Delta with Copanlisib Shows Preclinical Activity As a Single Agent and in Combination in Multiple Myeloma

Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)

Outcomes of Classical Hodgkin Lymphoma in US Hematology Practices: Initial Data from a Prospective Real-World Study

Activity of the Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Copanlisib, As a Single Agent and in Combination with Carfilzomib in Multiple Myeloma

Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications

Second-Generation Chimeric Antigen Receptors Successfully Modify Hematopoietic Stem Cells for Immunotherapy of B-Lineage Malignancies

Anti-CD19 Chimeric Antigen Receptor Controlled By The Suicide Gene HSVsr39TK In Hematopoietic Stem Cells For Immunotherapy Of B-Lineage Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only